
The Brexit Health Alliance (BHA) has cautioned that unless a favourable deal is struck, the UK could end Brexit negotiations …

Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that …

As we come to the end of January, it’s Friday again – time for another rundown of the top ten …

In a study published by the BMJ a few years ago, it was found that antibiotics were prescribed in 60% …

AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints …

An advisory panel of the FDA has judged that US tobacco firm Philip Morris International (PMI) has not been able …

Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …

Senescent cells are the dormant state that cells shift to in response to certain stressors, it is thought that they …

Novartis has confirmed a deal worth a potential $170 million with Spark Therapeutics to develop and commercialise its gene therapy …

There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible …

Alex Azar, President’s Trump’s controversial pick for Health and Human Services Secretary (HHS), has been confirmed in the role after …

The latest data from GW Pharma is about as conclusively positive as you can usually hope to get with a …

Research led by Georgia State University has enabled the development of a universal vaccine for influenza A viruses, proven to …

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

The administration of New York City Mayor Bill de Blasio has announced its intention to bring legal action against the …

Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …

NICE has said that a new online and mobile app should be trialled on the NHS in the treatment of …

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …

GlaxoSmithKline is celebrating as it emerges that the UK pharma giant triumphed in its legal battle against Reckitt Benckiser after …

In yet more bad news for Teva, it has emerged that two of the firm’s late-stage studies in asthma have …